<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Case Reports Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Case Reports Immunol</journal-id><journal-id journal-id-type="publisher-id">CRII</journal-id><journal-title-group><journal-title>Case Reports in Immunology</journal-title></journal-title-group><issn pub-type="ppub">2090-6609</issn><issn pub-type="epub">2090-6617</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25374741</article-id><article-id pub-id-type="pmc">4207470</article-id><article-id pub-id-type="doi">10.1155/2013/523865</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Rare Cause of Seizures, Renal Failure, and Gangrene in an 83-Year-Old Diabetic Male</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Viswanathan</surname><given-names>Stalin</given-names></name><xref ref-type="aff" rid="I1"/><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Balamurugesan</surname><given-names>Kandan</given-names></name><xref ref-type="aff" rid="I1"/></contrib></contrib-group><aff id="I1">Indira Gandhi Medical College, Kadhiramam, Pondicherry 605009, India</aff><author-notes><corresp id="cor1">*Stalin Viswanathan: <email>stalinviswanathan@ymail.com</email></corresp><fn fn-type="other"><p>Academic Editors: A. M. Mansour and H. Narimatsu</p></fn></author-notes><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>23</day><month>6</month><year>2013</year></pub-date><volume>2013</volume><elocation-id>523865</elocation-id><history><date date-type="received"><day>12</day><month>5</month><year>2013</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2013</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2013 S. Viswanathan and K. Balamurugesan.</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>We report an 83-year-old diabetic male who presented with acute-onset renal failure, seizures, psychosis, pneumonia, and right foot gangrene. Investigations revealed thrombocytopenia, CSF lymphocytosis, ANA and dsDNA positivity, hypocomplementemia, and pneumonitis following which he was treated with pulse methylprednisolone. He was treated for <italic>Pseudomonas</italic>-related ventilator-associated pneumonia, candiduria, and <italic>E. coli</italic>-related bedsore infection prior to discharge. He was discharged at request and died 17 days later due to a respiratory infection.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Onset of systemic lupus erythematosus (SLE) after the age of 50 (late-onset SLE) constitutes 6&#x02013;18% of the lupus population [<xref rid="B1" ref-type="bibr">1</xref>]. Most cases of lupus over 65 years have been described as case reports. Renal failure is the initial presentation only in 25% patients of SLE [<xref rid="B2" ref-type="bibr">2</xref>]. Neuropsychiatric SLE (NSLE) in the elderly is very rare. Infections, malignancies, and atherosclerotic disease account for most deaths in SLE patients [<xref rid="B3" ref-type="bibr">3</xref>]. Here we describe an 83-year-old diabetic who presented with acute-onset seizures, psychosis, pneumonitis, foot gangrene, and renal failure and improved with immunosuppressive therapy for SLE but succumbed to another respiratory infection 17 days after discharge from hospital.</p></sec><sec id="sec2"><title>2. Case</title><p>This 83-year-old diabetic of 10 years' duration (on metformin 750&#x02009;mg OD) was brought from another hospital by his relatives for mechanical ventilation. Fifteen days prior, he had complained of fatigue and anorexia and was admitted in a local nursing home where he was told to have early renal failure (creatinine 202&#x02009;<italic>&#x003bc;</italic>mol/L). Four days later he had had a generalized tonic-clonic seizure for which he was taken to the referring hospital for management. Computed tomography (CT) of brain was normal and the patient was commenced on phenytoin; he was uncooperative for magnetic resonance imaging (MRI). He had developed acute psychosis and delirium in hospital and was managed with risperidone. Three days later he was intubated for altered sensorium and respiratory distress following acute cough, breathlessness, and fever. He was mechanically ventilated and administered ceftriaxone and metronidazole; his seizures remained under control but altered sensorium persisted. During his stay in intensive care, he developed discoloration of his right foot and warfarin had been initiated. His renal parameters had continued to worsen (creatinine 350&#x02009;<italic>&#x003bc;</italic>mol/L) and his relatives requested discharge and brought him to our hospital.</p><p>He was a cigar smoker (&#x0003e;40 years) and drank occasionally. He had had a left hip fracture six years ago which had been treated conservatively. On admission, his pulse was 104&#x02009;bpm, BP 92/60&#x02009;mm&#x02009;Hg, respiratory rate 42 breaths/min with SpO<sub>2</sub> 92% on FiO2 of 100, temperature 99&#x000b0;F, and central venous pressure (CVP) was 6&#x02009;cm. Chest examination revealed left-sided coarse crackles. The Glasgow Coma Scale (GCS) of 2T/15, bilaterally 3&#x02009;mm sluggishly reacting pupils, generalized hypotonia, and areflexia were observed on neurological examination. There was no papilledema. He had dry gangrene of right foot (<xref ref-type="fig" rid="fig1">Figure 1</xref>) with weak right popliteal pulse. Investigations are listed in <xref ref-type="table" rid="tab1">Table 1</xref>. Doppler of right lower limb and echocardiography were normal. Pending cultures, he was initiated on piperacillin-tazobactam and levofloxacin, along with subcutaneous heparin, warfarin, and pentoxifylline. CT chest (day2) showed bilateral pleural thickening, bilateral ground glassing (right &#x0226b; left), airway dilatation, and reticulo-nodular infiltrates (right predominant) with minimal pleural effusion (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In view of seizures, psychosis, thrombocytopenia, renal failure, pneumonitis, ANA, and dsDNA positivity, a diagnosis of systemic lupus was made and pulse methyl prednisolone (1&#x02009;g &#x000d7; 3 days) was initiated on day 3, followed by oral steroids (60&#x02009;mg). Tracheal aspirate grew <italic>Pseudomonas aeruginosa</italic> and imipenem was administered on day 5 for probable ventilator-associated pneumonia. Weaning was done on 8th day of admission. Fluconazole 300&#x02009;mg/day was administered for persisting candiduria. Hypernatremia was managed with dextrose saline, while sugars were controlled with infusion of regular insulin. By day 12, his power had improved to 3/5 in all limbs; he occasionally spoke a few words to his relatives but continued to be extremely afraid of hospital personnel. MRI and nerve conduction studies could not be performed due to poor cooperation. He developed an infected gluteal bedsore (<italic>E. coli</italic>) that necessitated amikacin. We acceded to his son's request to be discharged to home with modified doses of intramuscular amikacin therapy, twice-daily premixed insulin, warfarin, phenytoin, risperidone, clonezepam, and oral prednisolone 40&#x02009;mg/day. Seventeen days later he succumbed to another respiratory infection.</p></sec><sec id="sec3"><title>3. Discussion</title><p>The 9&#x02009;:&#x02009;1 female predominance in SLE decreases prior to puberty and late in life [<xref rid="B4" ref-type="bibr">4</xref>]. Female&#x02009;:&#x02009;male ratio in late-onset SLE is about 5&#x02009;:&#x02009;1 [<xref rid="B5" ref-type="bibr">5</xref>], while another study showed a ratio of 1&#x02009;:&#x02009;1.1 when the age of onset was &#x0003e;65 years [<xref rid="B6" ref-type="bibr">6</xref>]. Four to 18% of cases from reported series are male [<xref rid="B7" ref-type="bibr">7</xref>]. In a Hong Kong study, the mean age of late-onset SLE was 62 years and onset was generally insidious [<xref rid="B1" ref-type="bibr">1</xref>]. Insidious onset of disease and lower index of suspicion lead to delayed diagnosis in the elderly. A study of 39 Indian male SLE subjects showed only one patient with late-onset SLE [<xref rid="B8" ref-type="bibr">8</xref>]. </p><p>It is generally agreed that SLE in the elderly is a mild disease [<xref rid="B9" ref-type="bibr">9</xref>]. Prevalence of organ involvement in males depends upon the ethnic population being studied, study setting (tertiary versus primary), selection criteria of female controls, and sample size of male subjects [<xref rid="B10" ref-type="bibr">10</xref>]. Fever, fatigue, and weight loss are common symptoms in elderly SLE patients [<xref rid="B5" ref-type="bibr">5</xref>]. Serositis, muscle pains, and arthritis are more common in this age group as are secondary Sj&#x000f6;gren's syndrome but with a lower incidence of cutaneous manifestations and Raynaud's phenomenon [<xref rid="B9" ref-type="bibr">9</xref>]. Males in a Thai study tended to have a shorter duration of symptoms prior to presentation, with alopecia, arthralgia and Raynaud's phenomenon being less common [<xref rid="B10" ref-type="bibr">10</xref>]. Psychosis, hypocomplementemia, and diffuse proliferative glomerulonephritis (DPGN) were less common in Indians [<xref rid="B8" ref-type="bibr">8</xref>], while renal disease and vascular thrombosis were common among Latin American males [<xref rid="B11" ref-type="bibr">11</xref>]. Rheumatoid arthritis, polymyalgia rheumatic, and sicca syndromes are close differentials of SLE in the elderly [<xref rid="B5" ref-type="bibr">5</xref>]. Late-onset lupus may have fewer major organ involvement and fewer major relapses [<xref rid="B12" ref-type="bibr">12</xref>].</p><p> Among patients with SLE, 60% of adults develop kidney disease [<xref rid="B2" ref-type="bibr">2</xref>]. SLE prevalence in India was low at 3.2/100000 population [<xref rid="B13" ref-type="bibr">13</xref>]; contrastingly, renal involvement among Indian SLE patients was the highest in the world [<xref rid="B13" ref-type="bibr">13</xref>]. Neuropsychiatric manifestations are similar in the young and the elderly [<xref rid="B9" ref-type="bibr">9</xref>]. Neuropsychiatric SLE (NSLE) at presentation in the elderly population has been described only as case reports. Similar to our case, seizures, coma, and pneumonia have been reported in a 72-year-old lady who had pneumonitis, hypocomplementemia, elevated fibrinogen, and FDP but with normal renal function and negative dsDNA [<xref rid="B14" ref-type="bibr">14</xref>]. Presence of NSLE is generally associated with a poor prognosis [<xref rid="B9" ref-type="bibr">9</xref>]. NSLE can be either focal (stroke, neuropathy, and transient ischemic attack) or diffuse (confusion, dementia, and psychosis) or can present with seizures (partial or generalized) [<xref rid="B9" ref-type="bibr">9</xref>]. Seizures are reported in 15 to 30% of patients with SLE [<xref rid="B9" ref-type="bibr">9</xref>]. Cognitive impairment may be the initial manifestation of SLE in the elderly [<xref rid="B5" ref-type="bibr">5</xref>]. The neurological manifestations seen in Indian studies were cerebrovascular accidents, myeloradiculopathies, movement disorders, seizures, coma, and psychosis [<xref rid="B13" ref-type="bibr">13</xref>]. Lower numbers of Raynaud and NSLE were seen in the South Indian population [<xref rid="B13" ref-type="bibr">13</xref>]. Our patient's cognition did not improve completely at time of discharge. His respiratory symptoms could have also been contributed by diabetes-related pneumonia or seizure-related aspiration pneumonia but his chest radiograph (<xref ref-type="fig" rid="fig1">Figure 1</xref>) cleared on the 4th day of admission (after two methyl prednisolone pulses). The cause of foot gangrene could not be pinpointed. Antiphospholipid antibody testing was unavailable in our hospital. Since warfarin had been initiated prior to admission, protein C and protein S were not done. High levels of D-dimer and FDP like in our patient may indicate vascular involvement due to emboli and/or inflammation [<xref rid="B14" ref-type="bibr">14</xref>]. It is possible that diabetes, old age, smoking, sepsis, and SLE predisposed him towards thrombosis.</p><p>Age did not affect serological findings in a study [<xref rid="B5" ref-type="bibr">5</xref>]. False positive ANA can be seen in the elderly [<xref rid="B5" ref-type="bibr">5</xref>]. Prevalence of dsDNA positivity and hypocomplementemia may be lower [<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B9" ref-type="bibr">9</xref>] and complement levels are inversely proportional to the age [<xref rid="B9" ref-type="bibr">9</xref>]. Our patient's C3 levels were borderline low, while ANA and dsDNA were positive. Anti-Ro and anti-La antibodies can be useful adjuncts in the elderly when dsDNA levels are less frequently positive [<xref rid="B9" ref-type="bibr">9</xref>]. The American Rheumatological Association (ARA) criteria may be too strict in the elderly population with NSLE and hence more attention is given to serology in the elderly [<xref rid="B15" ref-type="bibr">15</xref>]. Also, patients may not satisfy the current ARA classification criteria at presentation and hence diagnosis may be uncertain; they would need a longer duration of followup for the diagnosis to be made [<xref rid="B12" ref-type="bibr">12</xref>].</p><p>CNS disease and renal involvement contributed towards mortality [<xref rid="B3" ref-type="bibr">3</xref>]. Nonrenal factors like younger age, male sex, and hematological complications like thrombocytopenia were prognostic factors in lupus nephritis [<xref rid="B2" ref-type="bibr">2</xref>]. Cardiovascular disease and infections are common causes of mortality in the elderly [<xref rid="B5" ref-type="bibr">5</xref>]. In a retrospective Indian study, mortality in SLE patients was due to disease activity, infection, or both [<xref rid="B3" ref-type="bibr">3</xref>]. Hospital-acquired Gram-negative septicaemia contributed most in this study. Our patient had disease activity along with candiduria and <italic>Pseudomonas</italic>-related pneumonia which improved prior to discharge, but our patient finally succumbed to an infection. Septic shock due to high-dose immunosuppressants was the major cause of morality in older-onset SLE.</p><p>In conclusion, we report an elderly male diabetic with late-onset NSLE, gangrene, and sepsis (respiratory and urinary) that improved with immunosuppressant therapy. Systemic lupus erythematosus is an autoimmune disease involving women of childbearing age with highly variable clinical presentations and with 10% of cases occurring in older patients. Arthritis, fever, serositis, Raynaud's syndrome, lung disease, neuropsychiatric symptoms, positive antinuclear antibody tests, positive rheumatoid factor, positive anti-Ro/Sj&#x000f6;gren's syndrome (SS) A, and positive anti-La/SSB are more common in patients with elderly-onset lupus. Autoimmune diseases are very rare in elderly males and need to be considered in the differential diagnoses when confronted with multisystem disease even in the presence of diabetes and systemic sepsis. The diagnosis of elderly-onset lupus is often delayed for several months because of insidious onset and similarity to other more common disorders.</p></sec></body><back><sec sec-type="conflict"><title>Conflict of interests</title><p>The authors declare that they have no conflict of interests. </p></sec><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mak</surname><given-names>SK</given-names></name><name><surname>Lam</surname><given-names>EKM</given-names></name><name><surname>Wong</surname><given-names>AKM</given-names></name></person-group><article-title>Clinical profile of patients with late-onset SLE: not a benign subgroup</article-title><source><italic>Lupus</italic></source><year>1998</year><volume>7</volume><issue>1</issue><fpage>23</fpage><lpage>28</lpage><pub-id pub-id-type="other">2-s2.0-0031982694</pub-id><pub-id pub-id-type="pmid">9493145</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molino</surname><given-names>C</given-names></name><name><surname>Fabbian</surname><given-names>F</given-names></name><name><surname>Longhini</surname><given-names>C</given-names></name></person-group><article-title>Clinical approach to lupus nephritis: recent advances</article-title><source><italic>European Journal of Internal Medicine</italic></source><year>2009</year><volume>20</volume><issue>5</issue><fpage>447</fpage><lpage>453</lpage><pub-id pub-id-type="other">2-s2.0-68949192362</pub-id><pub-id pub-id-type="pmid">19712841</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Shamanna</surname><given-names>SB</given-names></name><name><surname>Kumar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Causes of mortality among inpatients with systemic lupus erythematosus in a tertiary care hospital in North India over a 10-year period</article-title><source><italic>Lupus</italic></source><year>2013</year><volume>22</volume><issue>2</issue><fpage>216</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">23192325</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name><name><surname>Chan</surname><given-names>TM</given-names></name><name><surname>Wong</surname><given-names>RWS</given-names></name></person-group><article-title>Clinical characteristics and outcome of southern Chinese males with systemic lupus erythematosus</article-title><source><italic>Lupus</italic></source><year>1999</year><volume>8</volume><issue>3</issue><fpage>188</fpage><lpage>196</lpage><pub-id pub-id-type="other">2-s2.0-0032892120</pub-id><pub-id pub-id-type="pmid">10342711</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazaro</surname><given-names>D</given-names></name></person-group><article-title>Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment</article-title><source><italic>Drugs and Aging</italic></source><year>2007</year><volume>24</volume><issue>9</issue><fpage>701</fpage><lpage>715</lpage><pub-id pub-id-type="other">2-s2.0-34548522473</pub-id><pub-id pub-id-type="pmid">17727302</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>SJ</given-names></name><name><surname>Luo</surname><given-names>S-F</given-names></name><name><surname>Wu</surname><given-names>YJJ</given-names></name><name><surname>Cheng</surname><given-names>HS</given-names></name><name><surname>Ho</surname><given-names>HH</given-names></name></person-group><article-title>The clinical features and prognosis of lupus with disease onset at age 65 and older</article-title><source><italic>Lupus</italic></source><year>2000</year><volume>9</volume><issue>2</issue><fpage>96</fpage><lpage>100</lpage><pub-id pub-id-type="other">2-s2.0-0034104879</pub-id><pub-id pub-id-type="pmid">10787005</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>G</given-names></name><name><surname>Vera-Lastra</surname><given-names>O</given-names></name><name><surname>Barile</surname><given-names>L</given-names></name><name><surname>Salas</surname><given-names>M</given-names></name><name><surname>Jara</surname><given-names>LJ</given-names></name></person-group><article-title>Clinical spectrum of males with primary antiphospholipid syndrome and systemic lupus erythematosus: a comparative study of 73 patients</article-title><source><italic>Lupus</italic></source><year>2004</year><volume>13</volume><issue>1</issue><fpage>11</fpage><lpage>16</lpage><pub-id pub-id-type="other">2-s2.0-1642460101</pub-id><pub-id pub-id-type="pmid">14870912</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pande</surname><given-names>I</given-names></name><name><surname>Malaviya</surname><given-names>AN</given-names></name><name><surname>Sekharan</surname><given-names>NG</given-names></name><name><surname>Kailash</surname><given-names>S</given-names></name><name><surname>Uppal</surname><given-names>SS</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name></person-group><article-title>SLE in indian men: analysis of the clinical and laboratory features with a review of the literature</article-title><source><italic>Lupus</italic></source><year>1994</year><volume>3</volume><issue>3</issue><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="other">2-s2.0-0028174780</pub-id><pub-id pub-id-type="pmid">7951303</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>M</given-names></name></person-group><article-title>Neuropsychiatric lupus erythematosus and the elderly</article-title><source><italic>International Journal of Geriatric Psychiatry</italic></source><year>1994</year><volume>9</volume><issue>2</issue><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="other">2-s2.0-0028084540</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mongkoltanatus</surname><given-names>J</given-names></name><name><surname>Wangkaew</surname><given-names>S</given-names></name><name><surname>Kasitanon</surname><given-names>N</given-names></name><name><surname>Louthrenoo</surname><given-names>W</given-names></name></person-group><article-title>Clinical features of Thai male lupus: an age-matched controlled study</article-title><source><italic>Rheumatology International</italic></source><year>2008</year><volume>28</volume><issue>4</issue><fpage>339</fpage><lpage>344</lpage><pub-id pub-id-type="other">2-s2.0-38049090620</pub-id><pub-id pub-id-type="pmid">17828538</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>MA</given-names></name><name><surname>Marcos</surname><given-names>JC</given-names></name><name><surname>Marcos</surname><given-names>AI</given-names></name><etal/></person-group><article-title>Male systemic lupus erythematosus in a Latin-American inception cohort of 1214 patients</article-title><source><italic>Lupus</italic></source><year>2005</year><volume>14</volume><issue>12</issue><fpage>938</fpage><lpage>946</lpage><pub-id pub-id-type="other">2-s2.0-30644472966</pub-id><pub-id pub-id-type="pmid">16425573</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>CTK</given-names></name><name><surname>Mok</surname><given-names>CC</given-names></name><name><surname>Lau</surname><given-names>CS</given-names></name><name><surname>Wong</surname><given-names>RWS</given-names></name></person-group><article-title>Late onset systemic lupus erythematosus in southern Chinese</article-title><source><italic>Annals of the Rheumatic Diseases</italic></source><year>1998</year><volume>57</volume><issue>7</issue><fpage>437</fpage><lpage>440</lpage><pub-id pub-id-type="other">2-s2.0-0011757525</pub-id><pub-id pub-id-type="pmid">9797573</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malaviya</surname><given-names>AN</given-names></name><name><surname>Chandrasekaran</surname><given-names>AN</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Shamar</surname><given-names>PN</given-names></name></person-group><article-title>Occasional series&#x02014;lupus around the world systemic lupus erythematosus in India</article-title><source><italic>Lupus</italic></source><year>1997</year><volume>6</volume><issue>9</issue><fpage>690</fpage><lpage>700</lpage><pub-id pub-id-type="other">2-s2.0-0031308964</pub-id><pub-id pub-id-type="pmid">9412983</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamaya</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Yamasaki</surname><given-names>M</given-names></name><name><surname>Kubo</surname><given-names>H</given-names></name><name><surname>Furukawa</surname><given-names>K</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name></person-group><article-title>Seizure and pneumonia in an elderly patient with systemic lupus erythematosus</article-title><source><italic>Journal of the American Geriatrics Society</italic></source><year>2009</year><volume>57</volume><issue>9</issue><fpage>1709</fpage><lpage>1711</lpage><pub-id pub-id-type="other">2-s2.0-69549110089</pub-id><pub-id pub-id-type="pmid">19895435</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>MS</given-names></name><name><surname>Byrne</surname><given-names>EJ</given-names></name><name><surname>Hopkinson</surname><given-names>N</given-names></name><name><surname>Bendall</surname><given-names>P</given-names></name></person-group><article-title>Neuropsychiatric systemic lupus erythematosus in elderly people: a case series</article-title><source><italic>Journal of Neurology Neurosurgery and Psychiatry</italic></source><year>1992</year><volume>55</volume><issue>12</issue><fpage>1157</fpage><lpage>1161</lpage><pub-id pub-id-type="other">2-s2.0-0027089887</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(a) Right foot discoloration at admission. (b) Right forefoot dry gangrene on day 4. (c) CT chest on day 2 showing airway dilatation (right predominant), patchy infiltrates, and ground glassing. (d) Chest radiograph on day 4 of admission shows clearing of infiltrates in the right side. (e) CT chest revealing right-sided pleural effusion, reticular infiltrates, bilateral ground glassing, and tree-in-bud appearance. (f) CT chest shows reticulonodular infiltrates in the entire right lung and ground glassing in left lung.</p></caption><graphic xlink:href="CRII2013-523865.001"/></fig><table-wrap id="tab1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Lab investigations of patient.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Day of admission</th><th align="center" rowspan="1" colspan="1"> 1</th><th align="center" rowspan="1" colspan="1"> 4 </th><th align="center" rowspan="1" colspan="1"> 5</th><th align="center" rowspan="1" colspan="1"> 7</th><th align="center" rowspan="1" colspan="1"> 10</th><th align="center" rowspan="1" colspan="1"> 16</th><th align="center" rowspan="1" colspan="1"> 18</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Urea (2.5&#x02013;7.1&#x02009;mmol/L)</td><td align="center" rowspan="1" colspan="1">67.8</td><td align="center" rowspan="1" colspan="1">61.7 </td><td align="center" rowspan="1" colspan="1">47.1</td><td align="center" rowspan="1" colspan="1">38.7</td><td align="center" rowspan="1" colspan="1">33.2</td><td align="center" rowspan="1" colspan="1">26.4</td><td align="center" rowspan="1" colspan="1">21.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Creatinine (44&#x02013;80&#x02009;<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="1" colspan="1">616</td><td align="center" rowspan="1" colspan="1">422</td><td align="center" rowspan="1" colspan="1">360</td><td align="center" rowspan="1" colspan="1">281</td><td align="center" rowspan="1" colspan="1">290</td><td align="center" rowspan="1" colspan="1">202</td><td align="center" rowspan="1" colspan="1">167</td></tr><tr><td align="left" rowspan="1" colspan="1">HbA1c (5.7&#x02013;6.5%)</td><td align="center" rowspan="1" colspan="1">7.9</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Bil total (1.7&#x02013;6.8&#x02009;<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="1" colspan="1">1.53</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Bil dir (3.4&#x02013;15.2&#x02009;<italic>&#x003bc;</italic>mol/L)</td><td align="center" rowspan="1" colspan="1">8.5</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">SGOT (0.20&#x02013;0.65&#x02009;<italic>&#x003bc;</italic>kat/L)</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">1.4</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">SGPT (0.12&#x02013;0.70&#x02009;<italic>&#x003bc;</italic>kat/L)</td><td align="center" rowspan="1" colspan="1">0.87 </td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.92 </td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">ALP (0.56&#x02013;1.63&#x02009;<italic>&#x003bc;</italic>kat/L)</td><td align="center" rowspan="1" colspan="1">3.88</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">9.02</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein (67&#x02013;86&#x02009;g/L)</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin (40&#x02013;50&#x02009;g/L)</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">GGT (0.15&#x02013;0.99&#x02009;<italic>&#x003bc;</italic>kat/L)</td><td align="center" rowspan="1" colspan="1">4.48</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">K<sup>+</sup> (3.5&#x02013;5.0&#x02009;mmol/L)</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">3.3</td><td align="center" rowspan="1" colspan="1">3.9</td><td align="center" rowspan="1" colspan="1">3.2</td><td align="center" rowspan="1" colspan="1">145</td><td align="center" rowspan="1" colspan="1">137</td><td align="center" rowspan="1" colspan="1">138</td></tr><tr><td align="left" rowspan="1" colspan="1">Na<sup>+</sup> (136&#x02013;146&#x02009;mmol/L)</td><td align="center" rowspan="1" colspan="1">155</td><td align="center" rowspan="1" colspan="1">151</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">143</td><td align="center" rowspan="1" colspan="1">5.7</td><td align="center" rowspan="1" colspan="1">3.8</td><td align="center" rowspan="1" colspan="1">3.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Calcium (2.2&#x02013;2.6&#x02009;mmol/L)</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Mg (0.62&#x02013;0.95&#x02009;mmol/L)</td><td align="center" rowspan="1" colspan="1">0.78</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Pi (0.81&#x02013;1.4&#x02009;mmol/L)</td><td align="center" rowspan="1" colspan="1">1.45</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">LDH (114&#x02013;240&#x02009;IU/L)</td><td align="center" rowspan="1" colspan="1">506</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">269</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">CK (25&#x02013;200&#x02009;U/L)</td><td align="center" rowspan="1" colspan="1">363</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">103</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Urine </italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Spot K<sup>+</sup> (25&#x02013;120&#x02009;mEq/L)</td><td align="center" colspan="7" rowspan="1">30.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Spot Na<sup>+</sup> (40&#x02013;220&#x02009;mEq/L)</td><td align="center" colspan="7" rowspan="1">116</td></tr><tr><td align="left" rowspan="1" colspan="1">Bence-Jones </td><td align="center" colspan="7" rowspan="1">Negative</td></tr><tr><td align="left" rowspan="1" colspan="1">Myoglobin </td><td align="center" colspan="7" rowspan="1">Negative</td></tr><tr><td align="left" rowspan="1" colspan="1">Heme </td><td align="center" colspan="7" rowspan="1">Negative </td></tr><tr><td align="left" rowspan="1" colspan="1">Eosinophils </td><td align="center" colspan="7" rowspan="1">Negative</td></tr><tr><td align="left" rowspan="1" colspan="1">Culture </td><td align="center" colspan="7" rowspan="1">3 organisms</td></tr><tr><td align="left" rowspan="1" colspan="1">Stool occult blood</td><td align="center" colspan="7" rowspan="1">Negative </td></tr><tr><td align="left" rowspan="1" colspan="1">Endotracheal asp AFB</td><td align="center" colspan="7" rowspan="1">Negative </td></tr><tr><td align="left" rowspan="1" colspan="1">Endotracheal asp culture</td><td align="center" colspan="7" rowspan="1">Pseudomonas</td></tr><tr><td align="left" rowspan="1" colspan="1">Hb (130&#x02013;160&#x02009;g/L)</td><td align="center" colspan="7" rowspan="1">81</td></tr><tr><td align="left" rowspan="1" colspan="1">TC (3.50&#x02013;9 &#x000d7; 10<sup>9</sup>/L)</td><td align="center" colspan="7" rowspan="1">10.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophilia (%)</td><td align="center" colspan="7" rowspan="1">81</td></tr><tr><td align="left" rowspan="1" colspan="1">Plat (165&#x02013;415 &#x000d7; 10<sup>9</sup>/L)</td><td align="center" colspan="7" rowspan="1">100</td></tr><tr><td align="left" rowspan="1" colspan="1">MCV (79&#x02013;93.3&#x02009;fL)</td><td align="center" colspan="7" rowspan="1">77</td></tr><tr><td align="left" rowspan="1" colspan="1">MCH (26.7&#x02013;31.9&#x02009;pg)</td><td align="center" colspan="7" rowspan="1">27.8</td></tr><tr><td align="left" rowspan="1" colspan="1">MCHC (323&#x02013;359&#x02009;g/L)</td><td align="center" colspan="7" rowspan="1">358</td></tr><tr><td align="left" rowspan="1" colspan="1">Reticulocyte (%)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">0.5</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">INR</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">1.3</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">aPTT (control 25.1&#x02009;s)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">D dimer (200&#x02009;ng/mL)</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">3200</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">FDP</td><td align="center" colspan="7" rowspan="1">Positive</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood cultures</td><td align="center" colspan="7" rowspan="1">Sterile </td></tr><tr><td align="left" rowspan="1" colspan="1">dsDNA (&#x0003c;20)</td><td align="center" colspan="7" rowspan="1">28</td></tr><tr><td align="left" rowspan="1" colspan="1">ANA (&#x0003c;1.0)</td><td align="center" colspan="7" rowspan="1">1.8</td></tr><tr><td align="left" rowspan="1" colspan="1">cANCA</td><td align="center" colspan="7" rowspan="1">Negative</td></tr><tr><td align="left" rowspan="1" colspan="1">C3 (0.83&#x02013;1.77&#x02009;g/L)</td><td align="center" colspan="7" rowspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1">C4 (0.16&#x02013;0.47&#x02009;g/L)</td><td align="center" colspan="7" rowspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">Cortisol (5&#x02013;25&#x02009;<italic>&#x003bc;</italic>g/dL)</td><td align="center" colspan="7" rowspan="1">26.1</td></tr><tr><td align="left" rowspan="1" colspan="1">Ferritin (28&#x02013;397&#x02009;ng/L)</td><td align="center" colspan="7" rowspan="1">1328</td></tr><tr><td align="left" rowspan="1" colspan="1">Direct Coombs</td><td align="center" colspan="7" rowspan="1">Negative </td></tr><tr><td align="left" colspan="8" rowspan="1">
<hr/>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>Cerebrospinal fluid </italic>
</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td><td align="center" rowspan="1" colspan="1">&#x02009;</td></tr><tr><td align="left" rowspan="1" colspan="1">Cells</td><td align="center" colspan="7" rowspan="1">103</td></tr><tr><td align="left" rowspan="1" colspan="1">Sugar (mg)</td><td align="center" colspan="7" rowspan="1">115</td></tr><tr><td align="left" rowspan="1" colspan="1">Protein (&#x0003c;60&#x02009;mg)</td><td align="center" colspan="7" rowspan="1">39</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphocytes (&#x0003c;5)</td><td align="center" colspan="7" rowspan="1">100%</td></tr><tr><td align="left" rowspan="1" colspan="1">ADA</td><td align="center" colspan="7" rowspan="1">1.0</td></tr><tr><td align="left" rowspan="1" colspan="1">AFB</td><td align="center" colspan="7" rowspan="1">Negative </td></tr><tr><td align="left" rowspan="1" colspan="1">Gram </td><td align="center" colspan="7" rowspan="1">Negative </td></tr><tr><td align="left" rowspan="1" colspan="1">India ink</td><td align="center" colspan="7" rowspan="1">Negative </td></tr></tbody></table><table-wrap-foot><fn><p>HbA1c: glycated haemoglobin; bil: bilirubin; dir: direct; SGOT: serum glutamic oxaloacetic transaminase; SGPT: serum glutamic pyruvate transaminase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transferase; K<sup>+</sup>: potassium; Na<sup>+</sup>: sodium; Mg: magnesium; Pi-inorganic phosphate; LDH: lactate dehydrogenase; CK: creatine kinase; Hb: haemoglobin; TC: total cells; plat: platelets; MCV: mean corpuscular volume; MCH: mean corpuscular haemoglobin; MCHC: mean corpuscular haemoglobin concentration; INR: international normalized ratio; aPTT: activated partial thromboplastin time; FDP: fibrinogen degradation products; dsDNA: double-stranded DNA; ANA: antinuclear antibody; c-ANCA: antineutrophil cytoplasmic autoantibody; C3: complement C3; C4: complement C4; ADA: adenosine deaminase; AFB: acid-fast bacilli; asp: aspirate.</p></fn></table-wrap-foot></table-wrap></floats-group></article>